Drug Trial Radar · NCT00870181
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Last checked: Nov 20, 2026Latest source record: Jun 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jan 2008
Primary completion
Dec 2011
Study completion Dec 2012
Sponsor
- Lead sponsor
- Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Tiantan Hospital; Beijing Chao Yang Hospital; Beijing Friendship Hospital
- First posted
- Mar 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.
Conditions
- Malignant Glioma of Brain
- Glioblastoma
Interventions
ADV-TK/GCVBiological
gene therapy
SurgeryProcedure
systemic chemotherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary end point was 6-month progression-free survival rate (PFS-6)Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing YouAn Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.